BiotechTube
TRIO Pharmaceuticals

TRIO Pharmaceuticals

New York, United States· Est.
triopharmaceuticals.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

TRIO Pharmaceuticals is a preclinical-stage biotech pioneering a novel class of dual-targeting antibodies designed to kill cancer cells more precisely while simultaneously overcoming the immunosuppressive tumor microenvironment. Its two core platforms, TIE-ADC™ and TRAILBody™, address key limitations of current therapies—toxicity and immune evasion—across a pipeline focused on AML/MDS, ovarian/endometrial cancer, TNBC, and NSCLC. Founded by experienced drug developers with prior successful exits, the company is positioned to advance its candidates toward clinical development, targeting areas of high unmet medical need.

Oncology

Technology Platform

Proprietary platforms for dual-targeting antibodies: 1) TIE-ADC™ (Tumor Immunity Enhancing Antibody-Drug Conjugate), a dual-targeting ADC designed to kill cancer cells and immunosuppressor cells simultaneously. 2) TRAILBody™, an antibody designed to selectively activate the TRAIL death receptor pathway on cancer cells to induce apoptosis without toxicity.

Opportunities

The significant unmet need in its target cancers (AML, ovarian, TNBC) allows for premium pricing and rapid adoption for a transformative therapy.
The dual-mechanism approach of TIE-ADC™ aligns with the growing trend of combination immuno-oncology, potentially offering a single-agent alternative to complex drug regimens.
The favorable safety profile suggested for TRAILBody™ could position it as a backbone therapy for combination use across multiple oncology indications.

Risk Factors

High preclinical risk: the novel mechanisms of action for both platforms are unproven in humans and may fail to demonstrate efficacy or reveal unexpected toxicities in clinical trials.
Intense competition from large pharmaceutical companies and other well-funded biotechs developing ADCs and immuno-oncology therapies in the same indications.
Dependence on future fundraising; as a private, pre-revenue company, inability to secure sufficient capital would halt development.

Competitive Landscape

TRIO operates in the highly competitive fields of antibody-drug conjugates (ADCs) and immuno-oncology. For TIE-ADC™, competitors include established ADC leaders like AstraZeneca/Daiichi Sankyo (Enhertu), Gilead, and a host of biotechs, as well as companies developing T-cell engagers and other immunomodulatory agents. For TRAILBody™, while the TRAIL pathway has been historically challenging to drug, competitors include companies developing next-generation TRAIL receptor agonists or other selective apoptosis inducers. TRIO's differentiation lies in its dual-targeting approach and aim for a superior therapeutic index.

More companies in Antibody-Drug Conjugates →More companies in United States →